随着基因重组人生长激素(rhGH)应用对象和适应证的日益广泛,长期生长激素(GH)治疗是否具有潜在致恶性肿瘤的危险,一直是争论和研究的焦点。目前现有的临床研究尚无确切证据证实GH治疗与恶性肿瘤的发生和复发有关,但有恶性肿瘤病史的患儿应警惕发生第二肿瘤的危险。对有危险因素的患儿应用GH治疗时,需密切监测胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3水平,保证GH更加安全和有效地应用。 With the increasing use of recombinant human growth hormone (rhGH) and indications, the risk of long-term growth hormone (GH) therapy being potentially malignant has been the subject of debate and research. At present, there is no conclusive evidence to confirm that GH treatment is related to the occurrence and recurrence of malignant tumors in existing clinical studies. However, children with a history of malignant tumors should be alert to the risk of developing a second tumor. GH treatment of children with risk factors, the need for close monitoring of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels, GH to ensure more safe and effective use.